Condition: Metastatic Colorectal Cancer · Sponsor: BeyondBio Inc.
This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).
This description comes directly from the study's public registry record.
BeyondBio Inc. · +82-42-716-0020 · clinicaltrials@beyondbio.co.kr
Always discuss trial participation with your own doctor first.
| Seoul National University Hospial | Seoul, Jongro-go, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05093907